Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) Target Price at $135.00

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are covering the company, MarketBeat reports. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $135.00.

A number of research analysts have recently issued reports on TMDX shares. Wall Street Zen downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Piper Sandler dropped their price objective on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. JPMorgan Chase & Co. boosted their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. TD Cowen dropped their price objective on TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Finally, Canaccord Genuity Group dropped their price objective on TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th.

Insider Buying and Selling

In related news, insider Nicholas Corcoran sold 2,966 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $412,629.92. Following the transaction, the insider owned 29,831 shares in the company, valued at $4,150,088.72. The trade was a 9.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Weill sold 3,571 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total transaction of $524,294.22. Following the transaction, the director owned 12,134 shares in the company, valued at $1,781,513.88. The trade was a 22.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,205 shares of company stock worth $2,353,002 over the last three months. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. D.A. Davidson & CO. raised its stake in TransMedics Group by 0.5% during the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock worth $1,865,000 after buying an additional 83 shares during the period. Parallel Advisors LLC raised its stake in TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares during the period. HighPoint Advisor Group LLC raised its stake in TransMedics Group by 3.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock worth $359,000 after buying an additional 88 shares during the period. Crossmark Global Holdings Inc. raised its stake in TransMedics Group by 4.0% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after buying an additional 88 shares during the period. Finally, Canada Pension Plan Investment Board raised its stake in TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Down 3.3%

Shares of TMDX opened at $62.04 on Friday. The company has a market capitalization of $2.14 billion, a PE ratio of 14.10 and a beta of 2.07. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The stock’s 50-day moving average price is $106.35 and its two-hundred day moving average price is $123.25. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). The company had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.70 earnings per share. On average, analysts anticipate that TransMedics Group will post 1.98 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.